Skip to content

A Study on the Effects of Virtual Reality Technology on Cognitive Function and Brain Function in Elderly Individuals with SCD

A Study on the Effects of Virtual Reality Technology on Cognitive Function and Brain Function in Elderly Individuals with SCD

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500103949
Enrollment
Unknown
Registered
2025-06-09
Start date
2025-06-20
Completion date
Unknown
Last updated
2025-06-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Subjective Cognitive Decline, SCD

Interventions

Test group:VR cognitive training (HTC Vive Pro) 30 minutes per session, 5 sessions per week × 4 weeks
Control group:Standard care plan for Alzheimers disease (including adjusting dietary structure and adopting a Mediterranean diet
controlling risk factors for cognitive decline, such as reducing sedentary behavior, increasing exercise and social interaction
paying attention to emotions and how to adjust them
and controlling underlying conditions such as hypertension, diabetes, and hyperlipidemia)

Sponsors

Rehabilitation Medical Center of Jiangsu Province Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
55 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Age 55–80 years old; (2) Primary school education or above, no visual or hearing impairments, able to cooperate in completing the assessment; (3) Overall cognitive function assessment: MOCA >= 26 points and SCD-Q9 >= 5 points; (4) Voluntarily participate in this study and sign an informed consent form .

Exclusion criteria

Exclusion criteria: (1) History of neuropsychiatric disorders, such as cerebrovascular disease, depression, schizophrenia, substance dependence, intracranial tumors, refractory epilepsy, Parkinson's disease, normal pressure hydrocephalus, brain tumors, and cranial trauma surgery; (2) Severe diseases of the heart, liver, kidneys, hematopoietic system, or endocrine system that significantly impair cognitive function; (3) MRI findings of cerebral infarction lesions, microbleeds, or space-occupying lesions; (4) Currently undergoing other non-pharmacological interventions.

Design outcomes

Primary

MeasureTime frame
Cognitive function;Specific cognitive domain (memory function);Specific cognitive domain (executive function);Specific cognitive domain (naming function);Activities of daily living;Imaging acquisition;Physiological data signal acquisition;Eye movement data acquisition ;Functional near-infrared device assessment;

Countries

China

Contacts

Public ContactZhu Yi

The First Affiliated Hospital of Nanjing Medical University, School of Nursing

lucky.zyx@163.com+86 137 0516 4030

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026